Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2047-9158
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study ; volume:9 ; number:1 ; day:28 ; month:4 ; year:2020 ; pages:1-3 ; date:12.2020
Translational neurodegeneration ; 9, Heft 1 (28.4.2020), 1-3, 12.2020
- Urheber
-
Reichmann, Heinz
Lees, Andrew
Rocha, José-Francisco
Magalhães, Diogo
Soares-da-Silva, Patrício
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40035-020-00193-3
- URN
-
urn:nbn:de:101:1-2020070821302031119704
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Reichmann, Heinz
- Lees, Andrew
- Rocha, José-Francisco
- Magalhães, Diogo
- Soares-da-Silva, Patrício
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Gender differences in non-motor fluctuations in Parkinson’s disease
Home monitoring of motor fluctuations in Parkinson’s disease patients
Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
Detecting motor symptom fluctuations in Parkinson’s disease with generative adversarial networks
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Gender differences in non-motor fluctuations in Parkinson’s disease
Home monitoring of motor fluctuations in Parkinson’s disease patients
Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
Detecting motor symptom fluctuations in Parkinson’s disease with generative adversarial networks
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Gender differences in non-motor fluctuations in Parkinson’s disease
Home monitoring of motor fluctuations in Parkinson’s disease patients
Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
Detecting motor symptom fluctuations in Parkinson’s disease with generative adversarial networks